Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Dusseldorf - Delayed Quote EUR

CStone Pharmaceuticals (PH4.DU)

0.3220
+0.0180
+(5.92%)
At close: April 23 at 7:30:39 PM GMT+2
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
463,842
463,842
481,363
243,718
1,038,832
Cost of Revenue
159,547
159,547
202,985
106,832
241,421
Gross Profit
304,295
304,295
278,378
136,886
797,411
Operating Expense
884,140
884,140
1,181,475
1,930,359
1,861,832
Operating Income
-579,845
-579,845
-903,097
-1,793,473
-1,064,421
Net Non Operating Interest Income Expense
13,067
13,067
1,195
7,561
22,841
Pretax Income
-367,234
-367,234
-902,678
-1,920,100
-1,220,999
Net Income Common Stockholders
-367,234
-367,234
-902,678
-1,920,100
-1,220,999
Diluted NI Available to Com Stockholders
-367,234
-367,234
-902,678
-1,920,100
-1,220,999
Basic EPS
-0.29
--
-0.77
-1.65
-1.17
Diluted EPS
-0.29
--
-0.77
-1.65
-1.17
Basic Average Shares
1,263,073
--
1,172,839
1,165,209
1,046,032
Diluted Average Shares
1,263,073
--
1,172,839
1,165,209
1,046,032
Rent Expense Supplemental
3,513
3,513
3,069
2,475
3,160
Total Expenses
1,043,687
1,043,687
1,384,460
2,037,191
2,103,253
Net Income from Continuing & Discontinued Operation
-367,234
-367,234
-902,678
-1,920,100
-1,220,999
Normalized Income
-546,426
-546,426
-840,749
-1,854,995
-1,223,416
Interest Income
24,886
24,886
9,672
9,803
24,161
Interest Expense
11,819
11,819
8,477
2,242
1,320
Net Interest Income
13,067
13,067
1,195
7,561
22,841
EBIT
-355,415
-355,415
-894,201
-1,917,858
-1,219,679
EBITDA
-297,225
-297,225
-849,661
-1,895,197
-1,204,878
Reconciled Cost of Revenue
159,547
159,547
202,985
106,832
241,421
Reconciled Depreciation
58,190
58,190
44,540
22,661
14,801
Net Income from Continuing Operation Net Minority Interest
-367,234
-367,234
-902,678
-1,920,100
-1,220,999
Total Unusual Items Excluding Goodwill
179,192
179,192
-61,929
-65,105
2,417
Total Unusual Items
179,192
179,192
-61,929
-65,105
2,417
Normalized EBITDA
-476,417
-476,417
-787,732
-1,830,092
-1,207,295
12/31/2020 - 6/25/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2VSA.DU Verastem Inc. R
6.35
+6.72%
 
473A.SG Adaptimmune Therapeutics PLC
0.2260
+2.73%
 
IMR.SG AC Immune SA
1.3560
+6.27%
 
3G0.BE Altimmune Inc
4.4110
+4.03%
 
F6T.SG Fate Therapeutics Inc
1.1970
+1.57%
 
MDG1.F Medigene AG
0.2190
+30.36%
 
TBPH Theravance Biopharma, Inc.
9.45
+1.50%
 
OCS Oculis Holding AG
17.89
+0.62%
 
VOR Vor Biopharma Inc.
0.7591
+8.13%
 
SCPH scPharmaceuticals Inc.
2.6000
-0.38%